Sharon Barr

Lizzy Lawrence, STAT’s FDA reporter, shares insights into the upheaval within the FDA, revealing how Robert F. Kennedy Jr.'s actions led to high-level resignations amidst a chaotic transition. Joining her is Sharon Barr, R&D executive at AstraZeneca, who discusses the promising results of a new PCSK9 pill that significantly reduces cholesterol, framing it as crucial for AstraZeneca’s growth strategy. The conversation also touches on the broader implications of leadership changes and market pressures in the biotech sector.